Antisynthetase syndrome

Curr Rheumatol Rep. 2011 Jun;13(3):175-81. doi: 10.1007/s11926-011-0176-8.

Abstract

Autoantibodies to eight of the aminoacyl-transfer RNA synthetases-the most well-recognized of which is anti-histidyl (Jo-1)-have all been implicated in the pathogenesis of antisynthetase syndrome (AS). AS is characterized by varying degrees of interstitial lung disease, myositis, arthropathy, fever, Raynaud's phenomenon, and mechanic's hands, and the morbidity and mortality of the disease are usually linked to the pulmonary findings. The value of a lung biopsy in AS cannot be overemphasized, as it serves to describe the underlying etiology of the interstitial lung disease, guide therapy, and estimate prognosis. Muscle disease shares many clinical features of polymyositis, yet histologically, the inflammatory involvement resembles that of dermatomyositis. Because inflammatory arthritis mimics rheumatoid arthritis, AS should be considered in atypical cases. Corticosteroids are the mainstay of acute therapy, although treatment often requires immunosuppressant medications such as cyclophosphamide, azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus, or rituximab.

Publication types

  • Review

MeSH terms

  • Amino Acyl-tRNA Synthetases / immunology*
  • Antibodies, Antinuclear / immunology*
  • Arthritis / immunology
  • Arthritis / pathology
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Lung / pathology
  • Lung Diseases, Interstitial / immunology
  • Lung Diseases, Interstitial / pathology
  • Myositis / drug therapy
  • Myositis / immunology
  • Myositis / pathology

Substances

  • Antibodies, Antinuclear
  • Glucocorticoids
  • Immunosuppressive Agents
  • Jo-1 antibody
  • Amino Acyl-tRNA Synthetases

Supplementary concepts

  • Antisynthetase syndrome